Zeidler, Jan; Mittendorf, Thomas; Müller, Rüdiger; … - In: Health Economics Review 2 (2012) 1, pp. 1-8
Marked differences in costs between subcutaneous and intravenous therapies were observed. Among the three groups of patients defined by TNF inhibitor treatment, costs for the infliximab group were highest during the year after the index event. </AbstractSection> Copyright Zeidler et al.; licensee Springer. 2012